Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan

[1]  R. Chow,et al.  Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis , 2016, Supportive Care in Cancer.

[2]  Y. Hirashima,et al.  Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy , 2015, BioMed research international.

[3]  Kazuhiro Yoshida,et al.  Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan , 2015, International Journal of Clinical Oncology.

[4]  E. Sato,et al.  Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy , 2014, Supportive Care in Cancer.

[5]  R. Navari,et al.  The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy , 2013, Supportive Care in Cancer.

[6]  M. Kris,et al.  Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  T. Perrone,et al.  Palonosetron (Aloxi®) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy , 2009, Supportive Care in Cancer.

[8]  G. de Pouvourville,et al.  Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics , 2004, Cancer.

[9]  M. Stockler,et al.  Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer , 2004, Supportive Care in Cancer.

[10]  David Khayat,et al.  Changing patient perceptions of the side effects of cancer chemotherapy , 2002, Cancer.

[11]  J. Verweij,et al.  Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy , 2001, British Journal of Cancer.

[12]  S B Kaye,et al.  On the receiving end--patient perception of the side-effects of cancer chemotherapy. , 1983, European journal of cancer & clinical oncology.

[13]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.